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Real-time high spatial resolution dose verification in stereotactic motion adaptive
arc radiotherapy
Abstract
Purpose: Radiation treatments delivered with real-time multileaf collimator (MLC) tracking currently lack
fast pretreatment or real-time quality assurance. The purpose of this study is to test a 2D silicon detector,
MagicPlate-512 (MP512), in a complex clinical environment involving real-time reconfiguration of the MLC
leaves during target tracking. Methods: MP512 was placed in the center of a solid water phantom and
mounted on a motion platform used to simulate three different patient motions. Electromagnetic target
tracking was implemented using the Calypso system (Varian Medical Systems, Palo Alto, CA, USA) and an
MLC tracking software. A two-arc VMAT plan was delivered and 2D dose distributions were reconstructed
by MP512, EBT3 film, and the Eclipse treatment planning system (TPS). Dose maps were compared using
gamma analysis with 2%/2 mm and 3%/3 mm acceptance criteria. Dose profiles were generated in supinf and lateral directions to show the agreement of MP512 to EBT3 and to highlight the efficacy of the
MLC tracking system in mitigating the effect of the simulated patient motion. Results: Using a 3%/3 mm
acceptance criterion for 2D gamma analysis, MP512 to EBT3 film agreement was 99% and MP512 to TPS
agreement was 100%. For a 2%/2 mm criterion, the agreement was 95% and 98%, respectively. Full width
at half maximum and 80%/20% penumbral width of the MP512 and EBT3 dose profiles agreed within 1
mm and 0.5 mm, respectively. Patient motion increased the measured dose profile penumbral width by
nearly 2 mm (with respect to the no-motion case); however, the MLC tracking strategy was able to
mitigate 80% of this effect. Conclusions: MP512 is capable of high spatial resolution 2D dose
reconstruction during adaptive MLC tracking, including arc deliveries. It shows potential as an effective
tool for 2D small field dosimetry and pretreatment quality assurance for MLC tracking modalities. These
results provide confidence that detector-based pretreatment dosimetry is clinically feasible despite fast
real-time MLC reconfigurations.

Disciplines
Engineering | Science and Technology Studies

Publication Details
Duncan, M., Newall, M. K., Caillet, V., Booth, J. T., Keall, P. J., Lerch, M., Perevertaylo, V., Rosenfeld, A. B. &
Petasecca, M. (2018). Real-time high spatial resolution dose verification in stereotactic motion adaptive
arc radiotherapy. Journal of Applied Clinical Medical Physics, 19 (4), 173-184.

Authors
Mitchell Duncan, Matthew Newall, Vincent Caillet, Jeremy T. Booth, Paul J. Keall, Michael L. F Lerch,
Vladimir Perevertaylo, Anatoly B. Rosenfeld, and Marco Petasecca

This journal article is available at Research Online: https://ro.uow.edu.au/eispapers1/1862

Received: 29 November 2017

|

Revised: 8 March 2018

|

Accepted: 18 April 2018

DOI: 10.1002/acm2.12364

RADIATION ONCOLOGY PHYSICS

Real-time high spatial resolution dose veriﬁcation in
stereotactic motion adaptive arc radiotherapy
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Paul J. Keall4 | Michael Lerch1 | Vladimir Perevertaylo5 | Anatoly B. Rosenfeld1 |
Marco Petasecca1
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Abstract
Purpose: Radiation treatments delivered with real-time multileaf collimator (MLC) track-

2

Northern Sydney Cancer Centre, Royal
North Shore Hospital, St. Leonards, NSW,
Australia

ing currently lack fast pretreatment or real-time quality assurance. The purpose of this
study is to test a 2D silicon detector, MagicPlate-512 (MP512), in a complex clinical envi-

3

ronment involving real-time reconﬁguration of the MLC leaves during target tracking.

4

on a motion platform used to simulate three different patient motions. Electromag-
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Methods: MP512 was placed in the center of a solid water phantom and mounted
netic target tracking was implemented using the Calypso system (Varian Medical
Systems, Palo Alto, CA, USA) and an MLC tracking software. A two-arc VMAT plan
was delivered and 2D dose distributions were reconstructed by MP512, EBT3 ﬁlm,
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and the Eclipse treatment planning system (TPS). Dose maps were compared using
gamma analysis with 2%/2 mm and 3%/3 mm acceptance criteria. Dose proﬁles
were generated in sup-inf and lateral directions to show the agreement of MP512
to EBT3 and to highlight the efﬁcacy of the MLC tracking system in mitigating the
effect of the simulated patient motion.
Results: Using a 3%/3 mm acceptance criterion for 2D gamma analysis, MP512 to
EBT3 ﬁlm agreement was 99% and MP512 to TPS agreement was 100%. For a 2%/
2 mm criterion, the agreement was 95% and 98%, respectively. Full width at half
maximum and 80%/20% penumbral width of the MP512 and EBT3 dose proﬁles
agreed within 1 mm and 0.5 mm, respectively. Patient motion increased the measured dose proﬁle penumbral width by nearly 2 mm (with respect to the no-motion
case); however, the MLC tracking strategy was able to mitigate 80% of this effect.
Conclusions: MP512 is capable of high spatial resolution 2D dose reconstruction
during adaptive MLC tracking, including arc deliveries. It shows potential as an
effective tool for 2D small ﬁeld dosimetry and pretreatment quality assurance for
MLC tracking modalities. These results provide conﬁdence that detector-based pretreatment dosimetry is clinically feasible despite fast real-time MLC reconﬁgurations.
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1 | INTRODUCTION

An alternative motion management approach in real-time ART
uses Calypso, the electromagnetic guided tumor tracking adopted by

Stereotactic body radiation therapy (SBRT), stereotactic ablative

Varian, and real-time beam modulation using the multileaf collimator

radiotherapy (SABR), and stereotactic radiosurgery (SRS) are highly

(MLC). The Calypso system detects and reconstructs the position of

conformal radiotherapy modalities for small tumors and functional

electromagnetic beacons implanted in proximity of the tumor vol-

abnormalities. They use a high dose per fraction (from 3 to 20 Gy)

ume.11,12

and fewer fractions than conventional external beam radiotherapy

The combination of Calypso and MLC tracking has been imple-

(EBRT) over the course of treatment. Field sizes are also typically

mented clinically at Royal North Shore Hospital (Sydney–Australia)

smaller

than

as a real-time tumor monitoring solution for ART. In 2013, MLC

4 9 4 cm2, where effects such as the loss of charged particle equi-

than

conventional

radiotherapy,

commonly

less

tracking was used for the ﬁrst time during a prostate VMAT treat-

librium (CPE) and partial source occlusion are present.

ment13 and more recently with lung SABR.14 In that study, the dose

SABR is often used to treat early-stage lung tumors.1 Patient res-

distribution was recalculated on the patient CT dataset using a

piration has been reported to affect target position by up to 30 mm

motion encoded treatment plan derived from analysis of the treat-

during EBRT.2 Intrafraction tumor motion can have a considerable

ment log ﬁles (dynalog). Results showed a reduction in the PTV size

impact on the dose delivered to the tumor volume and surrounding

by up to 40% and a reduction of mean dose to normal lung tissue of

healthy tissue,3 if motion is not compensated. Careful quality assur-

30%, compared to a standard ITV-based delivery.14

ance processes are essential in the application of such highly conformal radiotherapy modalities when tumor motion is present.4

Tracking techniques such as KIM and radiofrequency tracking
use feedback systems that may induce a signal in the chosen

Intrafraction tumor motion can be accommodated in the treat-

dosimeter, i.e., kV x rays and RF electromagnetic radiation, respec-

ment planning process using an extra margin called the internal target

tively. It is important that the dosimeter used during real-time ART

volume (ITV). This margin encompasses the entire volume occupied

is also unperturbed by these additional signals and only measures

by the moving tumor throughout several breathing cycles, obtained

the dose due to the MV treatment.

from 4DCT data. Inclusion of an ITV generally leads to a larger plan-

Small radiation ﬁelds introduce some extra dosimetry require-

ning target volume (PTV) and as a result, there is often more healthy

ments compared to larger ﬁelds. Namely high spatial resolution of

tissue irradiated compared to a treatment experiencing minimal

the detector array for use in steep dose gradients as well as small

tumor motion. Another approach to manage organ motion is gating

sensitive volume of a single detector, compared to beam size, to

the beam to treat only when the tumor is in a particular position.5-7

avoid volume averaging. The adopted dosimeter system should ide-

Real-time adaptive radiotherapy (ART) aims to treat the target volume with sensible margin reduction, in comparison to an ITV contouring, by monitoring the position and shape of the tumor continuously
throughout the treatment in order to modify the beam in real time.8

ally be close to tissue equivalent, so as not to perturb the
beam.15,16
There are several dosimeters that can potentially be used for
small ﬁeld dosimetry, each with their advantages and disadvantages.

The aim is to reduce the size of the ITV considerably, so that

EBT3 ﬁlm and Fricke or polymer-based gel have the required spa-

healthy tissue receives minimal dose, while at the same time deliver-

tial resolution for small ﬁeld dosimetry. They can give 2D and 3D dose

ing the correct dose to the target to achieve the highest possible

information, respectively; however, they lack a real-time readout.16,17

therapeutic outcome.

Ionization chambers can be read out in real time and can be cali-

Kilovoltage Intrafraction Monitoring (KIM) is one real-time moni-

brated for absolute dose; however, their spatial resolution and vol-

toring technique9; it uses the gantry equipped kV x-ray imager to

ume averaging effects can limit their use in high-resolution arrays for

monitor the position of the tumor in real time during treatment. An

small ﬁeld dosimetry.16

algorithm calculates the difference in tumor position from the cur-

Silicon diodes can be fabricated with a small sensitive volume;

rent and previous image to predict the target position in 3D. When

this means they can form 2D arrays with high spatial resolution. The

the tumor moves outside a predeﬁned tolerance, the treatment is

density of silicon is considerably higher than that of water, so energy

paused and the patient is repositioned through use of couch motion

dependence needs to be characterized as well as dose rate and

prior to resuming treatment.

angular dependence.18

There are several other possible strategies to manage patient

Log ﬁle analysis is a reasonable machine QA tool for MLC and

motion during EBRT, including pretreatment and intratreatment

gantry positional errors. However, it is unable to provide information

imaging, respiratory control devices or robotic couches.

on the position of a moving phantom relative to the beam or inde-

Recently, an extensive review was published of current motion
management strategies applied in the clinic.10

pendently evaluate the performance of an external tracking system,
such as Calypso.
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The Centre for Medical Radiation Physics (CMRP) at University

MP512 is a monolithic silicon detector which has an intrinsic

of Wollongong has developed a 2D monolithic silicon diode array

asymmetric structure creating an angular dependence, which needs

detector to be used for QA of small ﬁeld real-time ART: MagicPlate-

to be considered. Angular correction factors for 6 MV photons on a

512 (MP512). It has been designed to independently monitor exter-

Varian 2100iX linac have previously been obtained.21 The correction

nal beam radiotherapy treatments under complex clinical conditions

is valid for all MP512 devices; individual diode sensitivity is cor-

and reconstruct dose distributions in real time. It is capable of pulse-

rected pixel-by-pixel by a ﬂat ﬁeld prior to measurements. The rota-

by-pulse monitoring of the linac beam and has a spatial resolution

tion of the linac was independently monitored by an inclinometer

suitable for small ﬁeld dosimetry. It has been rigorously characterized

positioned on the gantry and synchronized with the data acquisition

for basic square ﬁelds in terms of percentage depth dose, output

system. This allowed for on-line correction of the detector response

factor, beam proﬁles, dose per pulse, and dose linearity.19 It has also

frame-by-frame.

been used with modulated IMRT ﬁelds, with a ﬁxed gantry angle
20

and a single patient motion applied.

To calibrate the detector, a dose linearity measurement in the

This study shows dosimetric

dose range 50 cGy to 1000 cGy was delivered at dmax in solid water

results from MP512 using a two-arc VMAT delivery with realistic

for a 10 9 10 cm2 ﬁeld size with 6 MV photons from a Varian

patient motions and tracking by the means of the Calypso localiza-

2100iX linac. Detector charge (nC) was plotted against dose (cGy)

tion system. Dose was delivered to a solid water phantom for three

and the slope of the linear relationship was used to deﬁne the dose

different patient motion traces obtained by 4DCT at Royal North

calibration factor.

Shore Hospital (Sydney–Australia). Dose maps obtained from MP512

The data acquisition system (DAQ) of the detector comprises of

were compared to EBT3 ﬁlm and treatment planning system

an analog front end (AFE) connected to an analog to digital con-

calculations.

verter. These are controlled by a ﬁeld programmable gate array
(FPGA) which also provides the de-randomization of the detector
channels, acquisition of the data from the inclinometer and data

2 | MATERIALS AND METHODS

packing for the USB2.0 interface used to communicate with a standard laptop. The AFE is a commercial chip from Texas Instruments

MP512 was placed in a solid water phantom on top of a movable

(Dallas, USA), the AFE0064, and features 64 current integrators

platform. Three patient motion traces were supplied to the platform

whose output is proportional to the charge collected on a variable

to simulate clinical lung motion during treatment delivery. Calypso

capacitor over a user-deﬁned integration time window. The DAQ

(Varian Medical Systems, Palo Alto, CA, USA) was used to monitor

features eight AFE chips, which are parallelized to readout the entire

the position of the phantom and real-time MLC tracking was used. A

detector at a maximum frame frequency of 7 kHz. The system can

two-arc VMAT plan was delivered for various motion modalities.

be synchronized with the linac electron gun pulse, so that current is

Dose was monitored in real-time with MP512 and compared to

integrated only when the beam is on, minimizing noise and allowing

EBT3 ﬁlm and the treatment planning system. Each component of

for measurement of the dose delivered by every linac pulse. Full

the experiment is described in more detail below.

speciﬁcations and benchmarking of the DAQ have been published
by Fuduli et al.22

2.A | MP512 detector array

A software control panel for the instrument was designed in
house using the Qt Creator Integrated Development Environment

MP512 (Figure 1) features a 52 9 52 mm2 array of 512 individual

(IDE) (The Qt Company — Espoo, Finland) based on C++. It manages

ion implanted silicon diodes on an epitaxial p-type silicon substrate.

all communication with the FPGA including deﬁnition of the integra-

Each diode has a sensitive area of 0.5 9 0.5 mm2 with 2 mm cen-

tion time, dynamic range, acquisition time, and frequency of mea-

ter-to-center distance. The detector is assembled on a 500 lm thick

surements. It also provides real-time visualization of the detector

printed circuit board which allows for mechanical rigidity and con-

response and allows for retrospective analysis of the data acquired.

nection of the readout electronics.

2.B | Reproducing organ motion
The patient lung motions were simulated using the 6D Hexamotion
movable platform by ScandiDos (Uppsala, Sweden) which provides
simultaneous motion in each of the x (left-right), y (sup-inf), and z
(ant-post) directions. Motion patterns were supplied by Northern
Sydney Cancer Centre (Royal North Shore Hospital, St Leonards
NSW) and were extracted from patient 4DCT data. For this study,
three motion patterns were used:
1. Patient 1: Lung trace with approximately 8 mm sup-inf offset
F I G . 1 . Rendering of MP512 detector mounted on printed circuit
board (PCB) and encapsulated in a PMMA phantom.

2. Patient 2: Lung trace centered around zero (null sup-inf offset)

176
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3. Patient 3: Lung trace with a predominant component in the lateral direction.
These motion traces were chosen as they represent three unique
types of respiration.
Figure 2 shows the motion traces as a function of time for each
patient in x, y, and z directions for approximately 80 s, corresponding to the time required to deliver the planned dose to the target.
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the ﬁeld shape in response to the detected motion of the target.13
Two different algorithms were input to the MLC controller: passive
feedback and predictive feedback. The passive feedback algorithm
calculates the position of the moving target based on information
from Calypso, and instructs the MLC controller to reconﬁgure the
beam aperture accordingly. There is a measurable latency of approximately 230 ms

13

between detection by Calypso and actuation of

the MLC leaves due to computation time and ﬁnite leaf speed,
meaning that the beam lags behind the real target trajectory. The

2.C | Motion tracking
MLC tracking is performed using the Calypso 4D localization system
(Varian Medical Systems — Palo Alto, CA, USA) for real-time monitoring of the target motion in conjunction with an MLC driving software developed at University of Sydney.23 Electromagnetic beacons
are used to determine the target position, this information is used
by the tracking software to signal the MLC controller to conﬁgure

predictive feedback algorithm uses kernel density estimation23 and a
short learning time frame in order to approximate the position of the
target, based on the difference between nominal and effective tumor
position. By predicting the target position at a time of T þ s (where
T is current time and s is a small increment of time) and setting
s ¼ 230 ms, the system latency is almost eliminated.20,24
Four tracking modalities were used to study the effect of motion
on the dose distribution:
1. No motion: phantom is static throughout the treatment delivery
2. Motion with no tracking: the phantom follows the supplied
motion trace and no MLC tracking is applied
3. Motion with passive tracking: the supplied motion trace is
adopted by the phantom and the MLC motion is controlled by
Calypso
4. Motion with predictive tracking: the phantom follows the supplied motion trace, Calypso tracking is activated and the predictive algorithm is used23 to minimize the delay between detected
motion and the corresponding MLC movement.

2.D | Detector encapsulation and phantom
MP512 was encased between two 5 mm thick sheets of PMMA for
structural rigidity (see Figure 1). There is an air gap above the sensitive volume to match the detector response to that of EBT3 ﬁlm for
small ﬁeld beams down to 1 9 1 cm

19,25

and to minimize the den-

sity and perturbation effects of silicon.26,27
An aluminum shielding box of 2 mm thickness was designed to
mitigate the baseline ﬂuctuations due to the electromagnetic (EM)
ﬁeld generated by Calypso.20 The time-varying EM ﬁeld induced a
current in the wiring and DAQ electronics, which contributed to
ﬂuctuations of the baseline signal (noise). The aluminum box covered
and sealed the entire detector and data acquisition system. Its effect
on dosimetry has been investigated by the means of Geant4 and
proved experimentally to have negligible effects at 1.5 cm water
equivalent depth and below.20 The phantom geometry is such that
the minimum thickness of solid water in the beams eye view is
1.5 cm throughout each arc.
The aluminum box was designed to allow 5 mm of solid water to
F I G . 2 . Three-dimensional lung motion traces corresponding to (a)
Patient 1, (b) Patient 2 and (c) Patient 3. Data are from 4DCT
sampled every 25 ms. X component corresponds to motion in leftright direction, Y component corresponds to motion in sup-inf
direction, and Z corresponds to motion in ant-pos direction.

be placed on top of the detector phantom, producing a water equivalent depth of approximately 1.5 cm, to simulate for example a chest
wall. The calculation of the water equivalent depth of the detector
(with beam normally incident to phantom surface, gantry at zero) is
shown in Eq. (1) where ti and qi are the thickness and density of

DUNCAN

|

ET AL.

177

comment on the effectiveness of MLC tracking versus ITV-based

T A B L E 1 Data for calculating water equivalent depth of the
detector sensitive volume.

planning in terms of clinical outcomes; hence, the same plan was
3

used for all modalities.

Material

Thickness (ti ) mm

Density (qi ) g/cm

PMMA

4

1.18

In Figure 4, a slice of the CT dataset incorporating the GTV and
PTV margins is shown. Figure 5 depicts the 2D dose map from

Solid Water

5

1.03

Aluminum

2

2.7

Eclipse overlaid on MP512 from a beam’s eye view (coronal plane).
The square regions overlaid on Figure 5 highlight the sensitive area
of the detector and correspond to the dose map position extracted

each of the materials, respectively. Data used in the calculation are

for comparison with the experimental results.

listed in Table 1.

d¼

X

2.F | Dosimetric measurements
ti  qi ¼ 15:27 mm

i

Equation 1: Calculation of water equivalent depth
The aluminum box was placed above 5 cm of solid water, ﬁgure 3 shows the cross-section of the detector phantom with the aluminum sheets and solid water blocks in place.

EBT3 ﬁlm was used to verify dose accuracy utilizing a gamma analysis of the 2D dose distributions. To coregister the dose maps, ﬁlm
sheets were sliced to the dimensions of the silicon detector and
inserted into the PMMA phantom. The airgap recess in the PMMA
phantom was common to both the detector and ﬁlm, so dose maps
were intrinsically coregistered. MATLAB was used to convert the
optical density of the ﬁlms to dose using a set of calibration ﬁlms.21

2.E | Treatment planning and delivery
Two VMAT arcs were used to deliver 496 MU and 508 MU at
6 MV on a Varian Clinac iX. The ﬁrst arc started at gantry angle 150
degrees, rotated in a counter-clockwise direction and stopped at 340
degrees, the second arc started at 340 degrees, rotated clockwise
and returned to 150 degrees. This beam arrangement allowed sufﬁcient target coverage while avoiding the treatment couch. A gross
tumor volume (GTV) was contoured manually around a hypothetical
spherical target of 2 cm diameter. The target’s center was aligned
with the central pixel of the detector. A PTV was deﬁned as a 3 mm
expansion of the GTV to create a clinically relevant lung plan while
allowing the contours to remain within the phantom geometry. The
Eclipse Treatment Planning System (TPS) (Varian Medical Systems —
Palo Alto, CA, USA), at Northern Sydney Cancer Centre was used to
generate a treatment plan which was inversely calculated on the CT
dataset of the phantom (Figure 4). A dose prescription of 5 Gy in a
single fraction was implemented. CT slice thickness was 1 mm and
dose was calculated using a 2-mm dose grid. No density overrides
were applied as there were no appreciable artifacts in the dataset.
Note that the same plan was delivered for all motion modalities, i.e.,
there was no ITV-based plan used for comparison. The aim of this
work was to characterize MP512 for use in adaptive arc modalities
using MLC tracking and gantry rotation. There was no intention to

F I G . 3 . Cross-section of scattering
conditions of the solid water phantom.
Units are mm. Detector surface is at an
approximate water equivalent depth of
1.5 cm and the solid PMMA phantom is
encapsulated by aluminum to minimize
induced noise from RF ﬁeld of Calypso.
Coordinate system is marked with the Y
direction coming out of the page.

Local gamma analysis was performed using a MATLAB script.
Gamma pass rates are reported for 2%/2 mm and 3%/3 mm dose
difference and distance to agreement criteria. The same method
was adopted to compare MP512 dose maps to the extracted 2D
dose maps from the TPS. Finally, a comparison was made of
MP512 dose maps for all motion modalities with respect to the nomotion case to quantify the accuracy in reconstructing the effects
of MLC tracking.
Dose proﬁles in the sup-inf and left-right (lateral) directions for
MP512 and EBT3 were plotted on the same axis for each motion
modality. The proﬁles were ﬁtted with a shape preserving polynomial
interpolation in MATLAB and aligned to 50% of the central axis dose
response. The ﬁt allows for accurate calculation of the full width at
half maximum (FWHM) and left and right penumbral width, i.e.,
width of the proﬁle between 80% response and 20% response. The
ﬁtting step used is 20 lm and the estimated accuracy for determination of the FWHM and penumbra width is approximately
0.25 mm. This corresponds to physical size of a single silicon
diode, which is approximately 0.5 9 0.5 mm2.
The baseline noise of the detector signal was determined to be
approximately 1%, the dose uncertainty of the EBT3 ﬁlm was calculated19 to be approximately 2% and error bars are reported on
the dose proﬁles, accordingly.

|
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F I G . 4 . GTV (blue) and PTV (red)
margins deﬁned on a CT dataset of the
detector phantom represented in a
transverse plane view. Directions are
indicated with Y (sup-inf) coming out of
page.

F I G . 5 . 2D dose map extracted from
Eclipse TPS overlaid on CT slice of MP512.
Boxes highlight the sensitive area of the
detector and represent the dose map
region used for gamma analysis
comparison (coronal plane views).

The effect of motion on dose response was analyzed by plotting
the point-to-point dose difference to show the areas of under and
over dose and to highlight the effect that each tracking modality had
on reducing these errors.

3 | RESULTS
3.A | Dose linearity
The response of MP512 to accumulated dose is shown in Figure 6.
The relationship of charge to dose in the 50 to 1000 cGy range is
linear. The MP512 measured charge is converted to dose using slope
of the linearity curve.

3.B | Gamma analysis
The integral dose maps obtained from EBT3, MP512, and TPS
are

shown

in

Figure 7.

Angular

corrections

were

applied

frame-by-frame to the MP512 response before integrating the

F I G . 6 . Linear dose response exhibited by MP512 for cumulative
dose delivery. The slope of the linear ﬁt is used to convert measured
detector charge (nC) to absorbed dose (cGy). Error bars indicate
measured baseline ﬂuctuation of 1%.

dose.
The gamma pass rates comparing EBT3 to MP512 and TPS
to MP512 for the no-motion case are shown in Table 2.
Table 3 shows the gamma analysis results for the three motion

3.C | Dose proﬁles measured by MP512 and EBT3
ﬁlm

patterns in respect to the no-motion case as measured by

In Figure 8, the dose proﬁles are illustrated in the vertical and hori-

MP512.

zontal directions of MP512 and EBT3 ﬁlm for each of the motion
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EBT3 Film

MP512

(a)

FIG. 7.

179

TPS

(b)

(c)

2D integral dose maps reconstructed from (a) EBT3, (b) MP512 and (c) TPS for the no-motion case.

T A B L E 2 Gamma pass rates for MP512 compared to TPS and
EBT3. Dose maps used correspond to the no-motion case
Tracking modality
No-motion

4 | DISCUSSION

2%-2mm (%)

3%-3mm (%)

Gamma analysis of the 2D dose maps from MP512 showed a very

TPS to MP512

98.44

100

close match to the 2D dose measured from EBT3 ﬁlm and dose

EBT3 to MP512

95.31

Comparison

99.31

extracted from Eclipse TPS. Using a 2%/2 mm acceptance criteria,
the response of MP512 matched that of EBT3 for 95% of points
and TPS for 98% of points. When a 3%/3 mm acceptance criterion

T A B L E 3 Gamma pass rates for MP512 vs MP512 response with
respect to the no-motion case for each motion modality

was used, the agreement was 99% and 100% for EBT3 and TPS,
respectively. This conﬁrms the accuracy of MP512 as a 2D dosime-

Motion trace

Tracking modality

2%-2mm (%)

3%-3mm (%)

try system even under complex clinical conditions. MP512 can

Patient 1

No tracking

78.65

98.44

reconstruct the dose delivered during realistic patient breathing with

Passive

98.96

99.83

real-time MLC tracking and full arc delivery. As a result, MP512 can

Predictive

98.44

99.65

No tracking

55.56

75.35

Passive

94.62

97.05

Patient 2

Patient 3

Predictive

96.01

98.09

No tracking

79.69

91.32

Passive

95.66

98.61

Predictive

93.23

96.35

be used as a tool to quantify the efﬁcacy of a particular tracking
regime, and in patient-speciﬁc pretreatment QA.
Gamma analysis was also performed on the MP512 measured
dose maps to intercompare each motion modality, this gives some
insight into the effect of MLC tracking.
Patient 1 motion (with no tracking) resulted in a pass rate of
78% (2%/2 mm); however, the two tracking modalities brought the
pass rate to 95% or above for both 3%/3 mm and 2%/2 mm acceptance criteria.
Patient 2 uncorrected motion had a pass rate of 55% (2%/2 mm)

modalities. The uncertainty in EBT3 ﬁlm measurement was calcu-

and Patient 3 had 80% pass rate (2%/2 mm) with motion. When

lated19 to be 2% and is within the size of the data points. Analysis

tracking was applied, pass rates of above 93% were observed for

of the baseline ﬂuctuation of MP512 produces an uncertainty of

both Patient 2 and Patient 3 for both criteria.

1%. Table 4 summarizes the analysis of the FWHM and penumbral
width for the dose proﬁles for the sup-inf direction.

Gamma pass rates above 95% for 3%/3mm agreement are commonly accepted as sufﬁcient to proceed with treatment.28 In our
case when the Patient 1 motion pattern was introduced, there was a

3.D | MP512 motion proﬁles

large drop in the 2%/2 mm pass rate when no tracking is applied;
however, the 3%/3 mm criteria was relatively unchanged at 98%. If

The proﬁles shown in Figure 9 highlight the effect of Patient 1

a gamma analysis using 3%/3mm acceptance criteria was the only

motion on the dose distribution. The proﬁles are reconstructed from

form of pretreatment QA for this plan, it appears to be clinically

MP512 for each motion modality. They are plotted on a single axis

acceptable. However, it is somewhat unlikely as this plan was

and the point-to-point dose difference is included in both cGy and

designed to be used in conjunction with MLC tracking and would

percentage to highlight areas of under and over dosage. The dose

not be used clinically when no tracking is to be applied, rather an

difference is referenced to the baseline no-motion case. The same

ITV-based plan would be created. This result still highlights the need

proﬁles are generated for Patients 2 and 3 in Figs 10 and 11,

to use caution when depending solely on gamma analysis (especially

respectively.

with a rather loose acceptance criterion) as a form of pretreatment
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No Motion
(b)

(a)

Motion
(c)

(d)

Passive Tracking
(e)

(f)

Predictive Tracking
(g)

F I G . 8 . MP512 vs EBT3 Dose Proﬁles
for various motion modalities with Patient
1 motion applied. Left Column: Proﬁles in
the sup-inf direction. Right Column:
Proﬁles in the left-right direction.

(h)
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QA. A similar conclusion was reached in previous studies29,30 which

correlation to errors in clinically relevant patient DVH metrics and

showed that gamma analysis pass rates for 3%/3 mm and 2%/2mm

even a 1%/1mm acceptance criteria only showed moderate

acceptance criteria for particular 2D dose planes had very little

correlation.

T A B L E 4 Summary of the comparison of FWHM and left and right
penumbral width between MP512 and EBT3 for dose proﬁles in the
vertical direction

a result, the data are available immediately after the measurement.

Right
Penumbra
(mm) 
0.3 mm

MP512 monitors the beam in real time, for every linac pulse. As
This information can be used to give insight into the efﬁcacy of a
particular tracking regime. For example, the results from the gamma
analysis show the predictive tracking algorithm did not always lead

Modality

Detector

FWHM
(mm)
0.3 mm

No-motion

EBT3

23.9

3.7

4.2

MP512

24.5

4.1

4.7

In our study, for periodic motion patterns, the predictive algo-

TPS

23.7

4.1

4.7

rithm had superior performance and gave better target tracking;

EBT3

24.0

5.3

5.4

however, for motion patterns that are aperiodic and erratic the pas-

MP512

24.6

5.7

5.9

sive tracking gave better results. We hypothesize this is due to the

0.6

0.3

0.5

difﬁculty in accurately predicting an irregular signal and depends on
the type and duration of the learning process adopted in the predic-

Motion

Difference
Passive tracking

EBT3

23.8

4.7

5.3

MP512

24.6

4.7

5.3

0

0

Difference
Predictive
tracking

Left Penumbra (mm) 
0.3 mm

0.8

EBT3

23.8

4.3

5.3

MP512

24.7

4.4

5.4

0.9

0.1

0.1

Difference

to a higher pass rate when compared to passive tracking, in this case
it was particularly dependent on the type of motion being experienced by the target volume.

tive algorithm.31 Some algorithms use an initial learning window
before treatment where the program learns the breathing trace over
a few respiratory cycles and others employ a dynamic type of learning which can adapt faster to irregularities in the motion.32
Dose proﬁles from MP512 and EBT3 ﬁlm undergoing Patient 1
motion were plotted on a single axis and compared (Figure 8). It was

F I G . 9 . Dose proﬁles measured with MP512 when the Patient 1 motion was applied for each motion modality, with dose error. Left
corresponds to Sup-Inf direction and right corresponds to Left-Right direction. In the error plots, NM corresponds to no motion, M to motion,
MT to motion tracking (i.e., passive algorithm) and MTP to motion tracking with prediction.
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F I G . 1 0 . Dose proﬁles measured with MP512 when the Patient 2 motion was applied for each motion modality, with dose error. Left
corresponds to vertical direction and right corresponds to horizontal direction. In the error plots, NM corresponds to no motion, M to motion,
MT to motion tracking (i.e., passive algorithm) and MTP to motion tracking with prediction.

found that in the sup-inf direction (major axis of organ motion due

Point-to-point dose difference plots were included to highlight

to the breathing cycle), the penumbral width of both proﬁles was

the dose error (in cGy and %) as a function of distance across the

within 0.5 mm and FWHM agrees within 1 mm for all deliveries.

proﬁle. This allowed for a quantitative measure of dose errors and

The agreement of data between MP512 and EBT3 ﬁlm over multiple

their locations, introduced by patient motion, and show the effec-

datasets further proves the accuracy of MP512 for use in adaptive

tiveness of the tracking system in reducing areas of under and over

therapy treatments.

dose. When motion was applied, there were under dose and over

MP512 measured dose proﬁles from each motion modality

dose regions of up to 280 cGy (45% of max dose) and 200 cGy

were plotted on a single axis, this allowed a qualitative overview

(35% of max dose) measured respectively, for a single fraction. The

of the effect of patient motion and MLC tracking on the dose

predictive tracking algorithm allowed the MLC to effectively com-

delivered. The effect of Patient 1 (Figure 9) motion on the dose

pensate for the motion, the dose discrepancies were reduced to just

distribution can clearly be identiﬁed through the spread of the

30 cGy which is 4.5% of the maximum dose. This represents a

proﬁle and loss of the dose distribution shape presented in the

reduction in dose error of up to 90% when tracking is applied com-

no-motion case. The discrepancy is quantiﬁed by an increase in

pared to the no-motion case.

left penumbral width of 1.62 mm compared to the no-motion

The effect of Patient 2 motion on the dose distribution is plotted

case. Passive tracking was able to reduce the penumbral width by

in Figure 10. The motion proﬁle is highly distorted with a triangular

60%. The predictive algorithm showed a reduction of 79%, an

shape and large areas of under and over dose, up to  200 cGy.

agreement within 0.34 mm of the no-motion case. The motion

These dose errors are halved from 20% of maximum dose to around

trace for Patient 1 is primarily in the vertical direction with a

10% when tracking is applied. There is not much effect from the

maximum

motion along the horizontal component due to the small contribu-

lateral

displacement

of

approximately

1.5 mm

(Figure 2a); because the lateral shift is smaller than the MLC leaf

tion of the motion in this direction.

width, it produces very little change in the proﬁles along the

Figure 11 shows the dose proﬁle when Patient 3 motion trace

horizontal direction and the tracking is not able to compensate

was applied. Due to the predominantly left-right component of this

for it.

breathing pattern, the vertical proﬁle is not largely affected;

DUNCAN

|

ET AL.

183

F I G . 1 1 . Dose proﬁles measured with MP512 when the Patient 3 motion was applied for each motion modality, with dose error. Left
corresponds to vertical direction and right corresponds to horizontal direction. In the error plots, NM corresponds to no motion, M to motion,
MT to motion tracking (i.e., passive algorithm) and MTP to motion tracking with prediction.

however, there is an overdose of 8% on the central axis in this direction when no tracking is applied which is reduced slightly to around
6% when tracking is activated.
The shift of the dose in the horizontal direction is evident in
this case due to the large lateral component of the motion trace.
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